Antidepressant-Like Effects of Erythropoietin: A Focus on Behavioural and Hippocampal Processes

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Osborn, Meagan ^a   Rustom, Nazneen ^a   Clarke, Melanie ^a   Litteljohn, Darcy ^a   Rudyk, Chris ^a   Anisman, Hymie ^a   Hayley, Shawn ^a  

^a CARLETON UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN; RECOMBINANT ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; EXPERIMENTAL TEST; FORCED SWIMMING TEST; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MALE; MAZE TEST; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; NOVELTY TEST; OPEN FIELD TEST; SOCIAL STRESS; TRANQUILIZING ACTIVITY;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; ERYTHROPOIETIN; HIPPOCAMPUS; MALE; MAZE LEARNING; MICE; SIROLIMUS; SWIMMING;

EID: 84883386093     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072813     Document Type: Article

References (74)

1. Campbell S, Marriott M, Nahmias C, MacQueen GM, (2004) Lower hippocampal volume in patients suffering from depression: a meta-analysis. Am J Psychiatry 161: 598-607. doi:10.1176/appi.ajp.161.4.598. PubMed: 15056502.
2. McEwen BS, (2000) Allostasis and allostatic load: implications for neuropsychopharmacology. Neuropsychopharmacology 22: 108-124. doi:10.1016/S0893-133X(99)00129-3. PubMed: 10649824.
3. Dranovsky A, Hen R, (2006) Hippocampal neurogenesis: regulation by stress and antidepressants. Biol Psychiatry 59: 1136-1143. doi:10.1016/j.biopsych.2006.03.082. PubMed: 16797263.
4. Duman RS, Monteggia LM, (2006) A neurotrophic model for stress-related mood disorders. Biol Psychiatry 59: 1116-1127. doi:10.1016/j.biopsych.2006.02.013. PubMed: 16631126.
5. Qian L, Block ML, Wei SJ, Lin CF, Reece J, et al. (2006) Interleukin-10 protects lipopolysaccharide induced neurotoxicity in primary midbrain cultures by inhibiting the function of NADPH oxidase. J Pharmacol Exp Ther 319: 44-52. doi:10.1124/jpet.106.106351. PubMed: 16807359.
6. Duman RS, Malberg J, Thome J, (1999) Neural plasticity to stress and antidepressant treatment. Biol Psychiatry 46: 1181-1191. doi:10.1016/S0006-3223(99)00177-8. PubMed: 10560024.
7. Altar CA, (1999) Neurotrophins and depression. Trends Pharmacol Sci 20: 59-61. doi:10.1016/S0165-6147(99)01309-7. PubMed: 10101965.
8. MacQueen GM, Campbell S, McEwen BS, Macdonald K, Amano S, et al. (2003) Course of illness, hippocampal function, and hippocampal volume in major depression. Proc Natl Acad Sci U S A 100: 1387-1392. doi:10.1073/pnas.0337481100. PubMed: 12552118.
9. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS, (2002) Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 22: 3251-3261. PubMed: 11943826.
10. Castrén E, Võikar V, Rantamäki T, (2007) Role of neurotrophic factors in depression. Curr Opin Pharmacol 7: 18-21. doi:10.1016/j.coph.2006.08.009. PubMed: 17049922.
11. Pandey GN, Dwivedi Y, Rizavi HS, Ren X, Zhang H, et al. (2010) Brain-derived neurotrophic factor gene and protein expression in pediatric and adult depressed subjects. Prog Neuropsychopharmacol Biol Psychiatry 34: 645-651. doi:10.1016/j.pnpbp.2010.03.003. PubMed: 20227453.
12. Groves JO, (2007) Is it time to reassess the BDNF hypothesis of depression? Mol Psychiatry 12: 1079-1088. doi:10.1038/sj.mp.4002075. PubMed: 17700574.
13. Evans SJ, Choudary PV, Neal CR, Li JZ, Vawter MP, et al. (2004) Dysregulation of the fibroblast growth factor system in major depression. Proc Natl Acad Sci U S A 101: 15506-15511. doi:10.1073/pnas.0406788101. PubMed: 15483108.
14. Elsayed M, Banasr M, Duric V, Fournier NM, Licznerski P, et al. (2012) Antidepressant effects of fibroblast growth factor-2 in behavioral and cellular models of depression. Biol Psychiatry 72: 258-265. doi:10.1016/j.biopsych.2012.03.003. PubMed: 22513055.
15. Matayoshi S, Jiang N, Katafuchi T, Koga K, Furue H, et al. (2005) Actions of brain-derived neurotrophic factor on spinal nociceptive transmission during inflammation in the rat. J Physiol 569: 685-695. doi:10.1113/jphysiol.2005.095331. PubMed: 16210356.
16. Pezet S, McMahon SB, (2006) Neurotrophins: mediators and modulators of pain. Annu Rev Neurosci 29: 507-538. doi:10.1146/annurev.neuro.29.051605.112929. PubMed: 16776595.
17. Constandil L, Aguilerab R, Goichb M, Hernándeza A, Alvarezb P, et al. (2011) Involvement of spinal cord BDNF in the generation and maintenance of chronic neuropathic pain in rats. Brain. Res Bull 86: 454-459. doi:10.1016/j.brainresbull.2011.08.008.
18. Yamashita K, Wiessner C, Lindholm D, Thoenen H, Hossmann KA, (1997) Post-occlusion treatment with BDNF reduces infarct size in a model of permanent occlusion of the middle cerebral artery in rat. Metab Brain Dis 12: 271-280. doi:10.1023/A:1022322025000. PubMed: 9475500.
19. Pardridge WM, Wu D, Sakane T, (1998) Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration. Pharm Res 15: 576-582. doi:10.1023/A:1011981927620. PubMed: 9587954.
20. Schmidt HD, Duman RS, (2010) Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models. Neuropsychopharmacology 12: 2378-2391. PubMed: 20686454.
21. Sargin D, Friedrichs H, El-Kordi A, Ehrenreich H, (2010) Erythropoietin as neuroprotective and neuroregenerative treatment strategy: comprehensive overview of 12 years of preclinical and clinical research. Best Pract Res Clin Anesthesiol, 24: 573-594. doi:10.1016/j.bpa.2010.10.005. PubMed: 21619868.
22. Hengemihle JM, Abugo O, Rifkind J, Spangler E, Danon D, et al. (1996) Chronic treatment with human recombinant erythropoietin increases hematocrit and improves water maze performance in mice. Physiol Behav 59: 153-156. doi:10.1016/0031-9384(95)02046-2. PubMed: 8848475.
23. Miskowiak K, O'Sullivan U, Harmer CJ, (2007) Erythropoietin enhances hippocampal response during memory retrieval in humans. J Neurosci 27: 2788-2792. doi:10.1523/JNEUROSCI.5013-06.2007. PubMed: 17360900.
24. Girgenti MJ, Hunsberger J, Duman CH, Sathyanesan M, Terwilliger R, et al. (2009) Erythropoietin induction by electroconvulsive seizure, gene regulation, and antidepressant-like behavioral effects. Biol Psychiatry 66: 267-274. doi:10.1016/j.biopsych.2008.12.005. PubMed: 19185286.
25. Miskowiak K, O'Sullivan U, Harmer CJ, (2007) Erythropoietin reduces neural and cognitive processing of fear in human models of antidepressant drug action. Biol Psychiatry 62: 1244-1250. doi:10.1016/j.biopsych.2007.01.011. PubMed: 17553466.
26. Miskowiak K, Inkster B, Selvaraj S, Wise R, Goodwin GM, et al. (2008) Erythropoietin improves mood and modulates the cognitive and neural processing of emotion 3 days post administration. Neuropsychopharmacology 33: 611-618. doi:10.1038/sj.npp.1301439. PubMed: 17473836.
27. Sanchez PE, Navarro FP, Fares RP, Nadam J, Georges B, et al. (2009) Erythropoietin receptor expression is concordant with erythropoietin but not with common beta chain expression in the rat brain throughout the life span. J Comp Neurol 514: 403-414. doi:10.1002/cne.22020. PubMed: 19330822.
28. Xiong Y, Mahmood A, Meng Y, Zhang Y, Qu C, et al. (2010) Delayed administration of erythropoietin reducing hippocampal cell loss, enhancing angiogenesis and neurogenesis, and improving functional outcome following traumatic brain injury in rats: comparison of treatment with single and triple dose. J Neurosurg 113: 598-608. doi:10.3171/2009.9.JNS09844. PubMed: 19817538.
29. Yan HC, Cao X, Gao TM, Zhu XH, (2011) Promoting adult hippocampal neurogenesis: a novel strategy for antidepressant drug screening. Curr Med Chem 18: 4359-4367. doi:10.2174/092986711797200471. PubMed: 21861813.
30. Byts N, Samoylenko A, Fasshauer T, Ivanisevic M, Hennighausen L, et al. (2008) Essential role for Stat5 in the neurotrophic but not in the neuroprotective effect of erythropoietin. Cell Death Differ 15: 783-792. doi:10.1038/cdd.2008.1. PubMed: 18259195.
31. Geslain R, Uddin S, Liu H, Jiang H, van Besien K, et al. (2013) Distinct functions of erythropoietin and stem cell factor are linked to activation of mTOR kinase signaling pathway in human erythroid progenitors. Cytokine 61: 329-335. doi:10.1016/j.cyto.2012.10.017. PubMed: 23148990.
32. Duman RS, Li N, Liu RJ, Duric V, Aghajanian G, (2012) Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 62: 35-41. doi:10.1016/j.neuropharm.2011.08.044. PubMed: 21907221.
33. Miskowiak KW, Favaron E, Hafizi S, Inkster B, Goodwin GM, et al. (2009) Effects of erythropoietin on emotional processing biases in patients with major depression: an exploratory fMRI study. Psychopharmacology 207: 133-142. doi:10.1007/s00213-009-1641-1. PubMed: 19705104.
34. Miskowiak KW, Favaron E, Hafizi S, Inkster B, Goodwin GM, et al. (2010) Erythropoietin modulates neural and cognitive processing of emotional information in biomarker models of antidepressant drug action in depressed patients. Psychopharmacology 210: 419-428. doi:10.1007/s00213-010-1842-7. PubMed: 20401747.
35. Miskowiak KW, Vinberg M, Harmer CJ, Ehrenreich H, Knudsen GM, et al. (2010) Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder. Trials 11: 97. doi:10.1186/1745-6215-11-97. PubMed: 20942940.
36. Estanislau C, Ramos AC, Ferraresi PD, Costa NF, de Carvalho HM, et al. (2011) Individual differences in the elevated plus-maze and the forced swim test. Behav Processes 86: 46-51. doi:10.1016/j.beproc.2010.08.008. PubMed: 20804831.
37. Hinojosa FR, Spricigo L Jr, Izídio GS, Brüske GR, Lopes DM, et al. (2006) Evaluation of two genetic animal models in behavioral tests of anxiety and depression. Behav Brain Res 168: 127-136. doi:10.1016/j.bbr.2005.10.019. PubMed: 16324754.
38. Millan MJ, (2006) Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application 110. Inst Pharm Therap. pp.: 135-370.
39. Miskowiak KW, Vinberg M, Harmer CJ, Ehrenreich H, Kessing LV, (2012) Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression. Psychopharmacology (Berl) 219: 687-698. doi:10.1007/s00213-011-2511-1. PubMed: 21947319.
40. Leconte C, Léger M, Boulouard M, Tixier E, Fréret T, et al. (2012) Repeated mild hypoxic exposures decrease anxiety-like behavior in the adult mouse together with an increased brain adrenomedullin gene expression. Behav Brain Res 230: 78-84. doi:10.1016/j.bbr.2012.01.054. PubMed: 22326698.
41. Leconte C, Bihel E, Lepelletier FX, Bouët V, Saulnier R, et al. (2011) Comparison of the effects of erythropoietin and its carbamylated derivative on behaviour and hippocampal neurogenesis in mice. Neuropharm 60: 354-364. doi:10.1016/j.neuropharm.2010.09.025. PubMed: 20932982.
42. Merali Z, Khan S, Michaud DS, Shippy S, Anisman H, (2004) Does amygdaloid corticotropin-releasing hormone (CRH) mediate anxiety-like behaviors? Dissociation of anxiogenic Effects and CRH Release Eur J Neurosci 20: 229-239.
43. Malberg JE, Eisch AJ, Nestler EJ, Duman RS, (2000) Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 20: 9104-9110. PubMed: 11124987.
44. Dremencov E, Gur E, Lerer B, Newman ME, (2003) Effects of chronic antidepressants and electroconvulsive shock on serotonergic neurotransmission in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 27: 729-739. doi:10.1016/S0278-5846(03)00123-4. PubMed: 12921903.
45. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, et al. (2003) Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301: 805-809. doi:10.1126/science.1083328. PubMed: 12907793.
46. Jacobs BL, (2002) Adult brain neurogenesis and depression. Brain Behav Immun 16: 602-609. doi:10.1016/S0889-1591(02)00015-6. PubMed: 12401475.
47. Bessa JM, Ferreira D, Melo I, Marques F, Cerqueira JJ, et al. (2009) The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling. Mol Psychiatry 14: 764-773. doi:10.1038/mp.2008.119. PubMed: 18982002.
48. Huang GJ, Bannerman D, Flint J, (2008) Chronic fluoxetine treatment alters behavior, but not adult hippocampal neurogenesis. BALB/CJ Mice Mol Psychiatry 13: 119-121. doi:10.1038/sj.mp.4002104.
49. Holick KA, Lee DC, Hen R, Dulawa SC, (2008) Behavioral effects of chronic fluoxetine in BALB/cJ mice do not require adult hippocampal neurogenesis or the serotonin 1A receptor. Neuropsychopharmacol 33: 406-417. doi:10.1038/sj.npp.1301399.
50. Bremner JD, Narayan M, Anderson ER, Staib LH, Miller HL, et al.((2000)) Hippocampal volume reduction in major depression. Am J Psychiatry 157: 115-118. PubMed: 10618023.
51. Sheline YI, Wang PW, Gado MH, Csernansky JG, Vannier MW, ((1996)) Hippocampal volume reduction in major depression. Proc Natl Acad Sci USA 93: 3908-3913. PubMed: PMC39458.
52. Sheline YI, Gado MH, Kraemer HC, (2003) Untreated depression and hippocampal volume loss. Am J Psychiatry 160: 1516-1518. doi:10.1176/appi.ajp.160.8.1516. PubMed: 12900317.
53. Caetano SC, Hatch JP, Brambilla P, Sassi RB, Nicoletti M, et al. (2004) Anatomical MRI study of hippocampus and amygdala in patients with current and remitted major depression. Psychiatry Res Neuroimaging 132: 141-147. doi:10.1016/j.pscychresns.2004.08.002. PubMed: 15598548.
54. D'Sa C, Duman RS, (2002) Antidepressants and neuroplasticity. Bipolar Disord 4: 183-194. doi:10.1034/j.1399-5618.2002.01203.x. PubMed: 12180273.
55. Jacobs BL, van Praag H, Gage FH, (2000) Adult brain neurogenesis and psychiatry: a novel theory of depression. Mol Psychiatry 5: 262-269. doi:10.1038/sj.mp.4000712. PubMed: 10889528.
56. Kempermann G, (2002) Why new neurons? Possible functions for adult hippocampal neurogenesis. J Neurosci 22: 635-638. PubMed: 11826092.
57. Gould E, Tanapat P, McEwen BS, Flügge G, Fuchs E, (1998) Proliferation of granule cell precursors in the dentate gyrus of adult monkeys is diminished by stress. Proc Natl Acad Sci U S A 95: 3168-3171. doi:10.1073/pnas.95.6.3168. PubMed: 9501234.
58. Kim JJ, Diamond DM, (2002) The stressed hippocampus, synaptic plasticity and lost memories. Nat Rev Neurosci 3: 453-462. doi:10.1038/nrm832. PubMed: 12042880.
59. Magariños AM, McEwen BS, Flügge G, Fuchs E, (1996) Chronic psychosocial stress causes apical dendritic atrophy of hippocampal CA3 pyramidal neurons in subordinate tree shrews. J Neurosci 16: 3534-3540. PubMed: 8627386.
60. McEwen BS, (1999) Stress and hippocampal plasticity. Annu Rev Neurosci 22: 105-122. doi:10.1146/annurev.neuro.22.1.105. PubMed: 10202533.
61. McEwen BS, (2000) The neurobiology of stress: from serendipity to clinical relevance. Brain Res 886: 172-189. doi:10.1016/S0006-8993(00)02950-4. PubMed: 11119695.
62. Stein-Behrens B, Mattson MP, Chang I, Yeh M, Sapolsky R, (1994) Stress exacerbates neuron loss and cytoskeletal pathology in the hippocampus. J Neurosci 14: 5373-5380. PubMed: 8083742.
63. Tanapat P, Galea LA, Gould E, (1998) Stress inhibits the proliferation of granule cell precursors in the developing dentate gyrus. Int J Dev Neurosci 16: 235-239. doi:10.1016/S0736-5748(98)00029-X. PubMed: 9785120.
64. Watanabe Y, Gould E, Cameron HA, Daniels DC, McEwen BS, (1992) Phenytoin prevents stress- and corticosterone-induced atrophy of CA3 pyramidal neurons. Hippocampus 2: 431-436. doi:10.1002/hipo.450020410. PubMed: 1308199.
65. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, et al. (2010) mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329: 959-964. doi:10.1126/science.1190287. PubMed: 20724638.
66. Han J, Wang B, Xiao Z, Gao Y, Zhao Y, et al. (2008) Mammalian target of rapamycin (mTOR) is involved in the neuronal differentiation of neural progenitors induced by insulin. Mol Cell Neurosci 39: 118-124. doi:10.1016/j.mcn.2008.06.003. PubMed: 18620060.
67. Zeng LH, Rensing NR, Wong M, (2009) The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J Neurosci 29: 6964-6972. doi:10.1523/JNEUROSCI.0066-09.2009. PubMed: 19474323.
68. Litteljohn D, Cummings A, Brennan A, Gill A, Chunduri S, et al. (2010) Interferon-gamma deficiency modifies the effects of a chronic stressor in mice: implications for psychological pathology. Brain Behav Immun 24: 462-473. doi:10.1016/j.bbi.2009.12.001. PubMed: 20004715.
69. Wen TC, Sadamoto Y, Tanaka J, Zhu PX, Nakata K, et al. (2002) Erythropoietin protects neurons against chemical hypoxia and cerebral ischemic injury by up-regulating Bcl-xL expression. J Neurosci Res 67: 795-803. doi:10.1002/jnr.10166. PubMed: 11891794.
70. Yiş U, Kurul SH, Kumral A, Tuǧyan K, Cilaker S, et al. (2008) Effect of erythropoietin on oxygen-induced brain injury in the newborn rat. Neurosci Lett 448: 245-249. doi:10.1016/j.neulet.2008.10.060. PubMed: 18973793.
71. Zhang F, Wang S, Cao G, Gao Y, Chen J, (2007) Signal transducers and activators of transcription 5 contributes to erythropoietin-mediated neuroprotection against hippocampal neuronal death after transient global cerebral ischemia. Neurobiol Dis 25: 45-53. doi:10.1016/j.nbd.2006.08.007. PubMed: 17008107.
72. Sadamoto Y, Igase K, Sakanaka M, Sato K, Otsuka H, et al. (1998) Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. Biochem Biophys Res Commun 253: 26-32. doi:10.1006/bbrc.1998.9748. PubMed: 9875214.
73. Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, et al. (1998) In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci U S A 95: 4635-4640. doi:10.1073/pnas.95.8.4635. PubMed: 9539790.
74. Ehrenreich H, Fischer B, Norra C, Schellenberger F, Stender N, et al. (2007) Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain 130: 2577-2588. doi:10.1093/brain/awm203. PubMed: 17728357.